AZN

AstraZeneca PLC

158.70 USD

Last updated Oct 9, 05:08 UTC

Yesterday HIGH

$161.29

Yesterday LOW

$158.53

52w HIGH

$212.71

52w LOW

$153.41

EPS

2.63

PE

60.34

Next Earnings

Oct 30, 2026

Overview News Unusual Options Flow Insider Transactions Government Trades Fundamentals

AstraZeneca PLC stock is up 1.12% since 30 days ago. The next earnings date is Oct 30, 2026. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 0% of the previous 1 October’s closed higher than September. In the last 10 Unusual Options Trades, there were 9 CALLs, 1 PUT.

Options Flow Last 10
Date & Time	Expiration Date	Strike Price	Trade Type	Size	Open Interest

06 Oct 15:47	17 Jun, 2027	160.00	CALL	17	186
06 Oct 15:53	17 Jun, 2027	160.00	CALL	18	186
06 Oct 17:07	15 Jan, 2027	170.00	CALL	76	3764
06 Oct 17:46	15 Jan, 2027	160.00	PUT	63	2227
06 Oct 18:33	20 Nov, 2026	165.00	CALL	75	182
07 Oct 14:11	17 Jun, 2027	160.00	CALL	50	146
07 Oct 15:29	17 Jun, 2027	160.00	CALL	30	146
08 Oct 13:36	19 Mar, 2027	160.00	CALL	30	2
08 Oct 13:43	21 Jan, 2028	160.00	CALL	24	86
08 Oct 15:26	16 Oct, 2026	160.00	CALL	147	1631

Advanced Data Unlock

Vandana Singh

Mon Sep 14, 2026

Cellectis Pivots to Gene Editing in Major Overhaul

Cellectis (NASDAQ: CLLS) pivots to in vivo gene editing, extending cash runway to H2 2028. Read pipeline updates on .HEAL-101 & .HEAL-201.
Vandana Singh

Mon Sep 14, 2026

Why Is AstraZeneca Stock Trading Higher Today?

AstraZeneca announced long-term survival data for Tagrisso and Enhertu in lung cancer, alongside breast cancer trial updates.
Benzinga Newsdesk

Mon Sep 14, 2026

Reported Earlier, AstraZeneca Says Tagrisso Reduces Risk Of Death By 48% Versus Placebo In Overall Stage IB-IIIA Trial Population, With 79% Alive At Eight Years Versus 64%

Longest survival data ever reported in a global Phase III trial in this settingNew data reinforce TAGRISSO as the standard of care and backbone therapy in EGFRm lung cancer across stages
Benzinga Newsdesk

Mon Sep 14, 2026

Reported Earlier, AstraZeneca And Daiichi Sankyo's Enhertu Cuts Risk Of Disease Progression Or Death By 37.0% Versus Pembrolizumab Plus Chemotherapy In Phase III Trial

6-month improvement in median progression-free survival vs. pembrolizumab plus chemotherapyAstraZeneca and Daiichi Sankyo’s ENHERTU is the first HER2-directed therapy to delay disease progression over standard of care
Avi Kapoor

Wed Sep 9, 2026

Jim Cramer: Reliance Is ‘Terrific,’ but He Prefers This Steel Stock

Cramer avoids AstraZeneca, Joby and Grab; favors Trinity, Nucor over Reliance, and praises Simon Property and Federal Realty.
Vandana Singh

Tue Sep 8, 2026

Astrazeneca Secures FDA Approval for New Breast Cancer Treatment

AstraZeneca secured FDA approval for its breast cancer drug Etcamah and reported positive Phase 3 trial data for lung cancer and COPD.
Benzinga Newsdesk

Tue Sep 8, 2026

AstraZeneca Says Phase 3 DeLLphi-305 Interim Analysis Showed IMFINZI Plus Amgen's Tarlatamab Met Primary Endpoint With Statistically Significant Overall Survival Improvement vs. IMFINZI Alone In Extensive-Stage Small Cell Lung Cancer
Benzinga Newsdesk

Tue Sep 8, 2026

AstraZeneca Announces Tozorakimab Demonstrates Reduction In Participants With Chronic Obstructive Pulmonary Disease In Phase III OBERON, TITANIA Studies

https://www.astrazeneca.com/media-centre/press-releases/2026/tozorakimab-demonstrated-statistically-significant-highly-clinically-meaningful-reduction-copd-exacerbations-oberon-titania-phase-iii-trials.html
Benzinga Newsdesk

Fri Sep 4, 2026

FDA Grants Accelerated Approval To Etcamah For Advanced Breast Cancer With ESR1 Mutation; Authorizes Guardant360 CDx Assay As Companion Diagnostic For Breast Cancer

https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-new-breast-cancer-treatment
Vandana Singh

Tue Sep 1, 2026

AstraZeneca Shares Dual Oncology Clinical and Regulatory Victories

AstraZeneca announced positive Phase 3 lung cancer trial results and earned EU approval for its Enhertu breast cancer combination.

Mani Sharma, See Remarks

Sat Aug 8, 2026

AZN Recent Insider Trades and Stock Chart

20.23 shares bought
Mani Sharma, See Remarks

Tue Sep 8, 2026

AZN Recent Insider Trades and Stock Chart

1 shares awarded